Comparison of K-ras mutations in lung, colorectal and gastric cancer

Peng,Nanqiu; Zhao,Xintai

doi:10.3892/ol.2014.2205

Comparison of K-ras mutations in lung, colorectal and gastric cancer

Authors:
- Nanqiu Peng
- Xintai Zhao
View Affiliations

Affiliations: Technical Department, Shanghai Shines Pharmaceuticals Company Limited, Research Base of Molecular Diagnosis Technology for Tumor Personalized Therapy, Development Center for Medical Science and Technology, Ministry of Health, Shanghai 201900, P.R. China
Published online on: May 30, 2014 https://doi.org/10.3892/ol.2014.2205
Pages: 561-565

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

K-ras is involved in the EGFR pathway that regulates cell survival, motility and proliferation, as well as angiogenesis and metastasis. It is also essential for carcinogenesis. The K-ras mutation status can be used to predict the therapeutic efficacy of targeted drugs such as cetuximab. The aim of this study was to compare K-ras mutation in different types of cancer. Nested and COLD-PCR were used to detect K-ras mutations. The Chi-squared test was used for statistical analysis. In this study, the total K-ras mutation frequency was found to be 9.09, 18.61 and 6.67% in lung, colorectal and gastric cancer, respectively. Similar K-ras mutation frequencies were detected among sample types and genders for lung and gastric cancer, with the exception of colorectal cancer. However, age had no impact on the K-ras mutation rates.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011.
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013.
3	Kiaris H and Spandidos DA: Mutations of ras genes in human tumours. International Journal of Oncology. 7:413–429. 1995.
4	Schubbert S, Shannon K and Bollag G: Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 7:295–308. 2007.
5	Bos JL, Fearon ER, Hamilton SR, et al: Prevalence of ras gene mutations in human colorectal cancers. Nature. 327:293–297. 1987.
6	Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 67:2643–2648. 2007.
7	Lilleberg SL, Durocher J, Sanders C, Walters K and Culver K: High sensitivity scanning of colorectal tumors and matched plasma DNA for mutations in APC, TP53, K-RAS, and BRAF genes with a novel DHPLC fluorescence detection platform. Ann NY Acad Sci. 1022:250–256. 2004.
8	Mostert B, Jiang Y, Sieuwerts AM, et al: KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer. 133:130–141. 2013.
9	Abdul Murad NA, Othman Z, Khalid M, et al: Missense mutations in MLH1, MSH2, KRAS, and APC genes in colorectal cancer patients in Malaysia. Dig Dis Sci. 57:2863–2872. 2012.
10	Sinha R, Hussain S, Mehrotra R, et al: Kras gene mutation and RASSF1A, FHIT and MGMT gene promoter hypermethylation: indicators of tumor staging and metastasis in adenocarcinomatous sporadic colorectal cancer in Indian population. PLoS One. 8:e601422013.
11	Bando H, Yoshino T, Tsuchihara K, et al: KRAS mutations detected by the amplification refractory mutation system-Scorpion assays strongly correlate with therapeutic effect of cetuximab. Br J Cancer. 105:403–406. 2011.
12	Li J and Makrigiorgos GM: COLD-PCR: a new platform for highly improved mutation detection in cancer and genetic testing. Biochem Soc Trans. 37:427–432. 2009.
13	Zuo Z, Chen SS, Chandra PK, et al: Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol. 22:1023–1031. 2009.
14	Carotenuto P, Roma C, Cozzolino S, et al: Detection of KRAS mutations in colorectal cancer with Fast COLD-PCR. Int J Oncol. 40:378–384. 2012.
15	Pennycuick A, Simpson T, Crawley D, et al: Routine EGFR and KRAS mutation analysis using COLD-PCR in non-small cell lung cancer. Int J Clin Pract. 66:748–752. 2012.
16	Allegra CJ, Jessup JM, Somerfield MR, et al: American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 27:2091–2096. 2009.
17	De Roock W, Claes B, Bernasconi D, et al: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11:753–762. 2010.